Frontline Standard of Care in PD-L1+ Metastatic Triple-Negative Breast Cancer (mTNBC): Antibody-Drug Conjugates (ADCs) vs Chemotherapy
In this debate moderated by Dr Tiffany Traina, Drs Sonya Reid and Seth Wander discuss treating metastatic triple-negative breast cancer (mTNBC) with the use of antibody-drug conjugates (ADCs) vs chemotherapy as a frontline therapy.
Introduction:
In this introduction, Dr Tiffany Traina sets the stage for the session by outlining the current standard of care for programmed cell death protein 1-positive (PD-L1+) mTNBC
Round 1:
Drs Sonya Reid and Seth Wander debate whether an ADC-based regimen is considered the new standard of care in PD-L1+ mTNBC.
Round 2:
Drs Sonya Reid and Seth Wander debate whether institutions, payers, and clinicians can pivot fast enough to adopt ADC-based regimens into everyday practice.
©2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
